Contact | Print version | PDF version | Send article | RSS feed

BioLineRx Initiates Phase I/II Trial of BL-5010 for the Non Surgical Removal of Skin Lesions

22 Jun 2009 - BioLineRx, a drug development company with products in advanced clinical and pre-clinical testing, announced the initiation of a Phase I/II clinical trial aimed at assessing the safety and efficacy of BL-5010, a novel formulation for the non surgical removal of skin lesions.
 
The open-label, single arm trial will be conducted in 60 patients with seborrheic keratosis in Germany and the Netherlands. The objectives of the study are to determine the safety and tolerability of the BL-5010 formulation and to assess its efficacy in completely removing the lesion. In addition, we will assess BL-5010’s efficacy in preserving the cellular structure of the lesion for subsequent histological examination. The study is scheduled to start in June, 2009. Interim results from the first 25 patients are expected in the fourth quarter of 2009.